Phase 3 MAESTRO-NAFLD-1 Data for Resmetirom in MASH Cirrhosis, with Naim Alkhouri, MD
Alkhouri reviews data from the trial’s open-label compensated MASH cirrhosis arm demonstrating resmetirom’s impact on liver stiffness and CSPH.
Related Articles
Mezagitamab Shows Promise for IgA Nephropathy in Phase 1b Trial, with Jonathan Barratt, MD, PhD
Jonathan Barratt, MD, PhD, discusses results from an open-label trial of mezagitamab from ERA 2025.
RaDaR Validation Confirms PARASOL Findings on FSGS Surrogate Endpoint, with Daniel Gale, PhD, MB BChir
A study presented at ERA 2025 validates the use of proteinuria as a surrogate endpoint for FSGS clinical trials.
Phase 3 ORIGIN Sets Stage for Atacicept in IgA Nephropathy, with Richard Lafayette, MD
Richard Lafeyette, MD, discusses his reaction to the phase 3 ORIGIN topline results and what it means for IgAN.
Improving Incidental Lung Nodule Follow-up, with Javier Zulueta, MD
Zulueta discussed Mount Sinai’s incidental lung nodule program using AI tools to improve follow-up and recent findings from the program presented at ATS.
Kidney Compass: Sibeprenlimab and the VISIONARY Trial, with Vlado Perkovic, MBBS, PhD, at ERA 2025
Discover groundbreaking insights on the VISIONARY trial, IgA nephropathy treatment, and the future of kidney care with expert Vlado Perkovic, MBBS, PhD.
Staggered Schedule May Not Harm Firefighter Sleep, Nicole Bowles, PhD, Says
HCPLive spoke with Bowles at SLEEP 2025 on the staggered schedule, referred to as 1/3/2/3, and how it impacts firefighters’ sleep.
ERA 2025: Sibeprenlimab Halves Proteinuria in IgAN in Phase 3 VISIONARY Trial
Prespecified analysis of 320 patients in VISIONARY were presented at ERA 2025 Congress.
Debating the Usefulness of ACE/ARBs in Kidney & Cardiovascular Disease with Matthew Weir, MD
With so many new medications ostensibly filling the niche typically occupied by ACE/ARBs, are the medications practically useful in a changed treatment landscape?
Integrating Novel Treatments to Advance Schizophrenia Management
Gus Alva, MD and Hara Oyedeji, PMHNP-BC, APRN, MSN, MSEd discuss how schizophrenia encompasses three distinct symptom domains beyond just hallucinations, the limitations of current…
Treating Insomnia First May Be Key to Effective PTSD Therapy, with Peter Colvonen, PhD
HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.